The Center for Biologics Evaluation and Research Freedom of Information Act (FOIA) Electronic Reading Room contains copies of CBER records (or links to other locations of CBER records) that we are making publicly available: (1) because the records are required to be published on the web by the Food, Drug and Cosmetic Act, (2) because they are “frequently requested” records under the FOIA (5 U.S.C. § 552(a)(2)(D)) or (3) proactively at our discretion. We will continue to add records to reflect public interest.
Information of Interest
Frequently Requested Records*
* - The Freedom of Information Act, 5 U.S.C. § 552(a)(2)(D) “copies of all records, regardless of form or format - (i) that have been released to any person under paragraph (3); and (ii)(I) that because of the nature of their subject matter, the agency determines have become or are likely to become the subject of subsequent requests for substantially the same records; or (II) that have been requested 3 or more times;”
|Date Posted||Records Description|
|08/15/2022||Bavarian Nordic A/S Response Letter - August 12, 2022|
|09/21/2021||FDA Form 483 Novartis Morris Plains NJ April 2017|
|09/21/2021||FDA Form 483 Cangene Corp Winnipeg Canada May 2017|